Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoxic cell turnover in different solid tumor lines.

Anna S E Ljungkvist1, Johan Bussink, Johannes H A M Kaanders

  • 1Department of Radiation Oncology, Radboud University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands. a.ljungkvist@rther.umcn.nl

International Journal of Radiation Oncology, Biology, Physics
|May 26, 2005
PubMed
Summary

Tumor hypoxia impacts radiotherapy outcomes. This study found hypoxic cell turnover rates vary significantly among tumor types, with half-lives ranging from 17-49 hours, informing treatment scheduling.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondria-targeted OXPHOS inhibition enhances radiotherapy efficacy by disrupting mitochondrial function.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8<sup>+</sup> T-cell infiltration.

Immunotherapy advances·2026
Same author

Recommendations for contouring of gross tumour volume for locally advanced lung cancer using magnetic resonance imaging.

Physics and imaging in radiation oncology·2026
Same author

CAIX-targeted α therapy directed against hypoxic tumor cells in combination with immune checkpoint inhibitors in a syngeneic mouse tumor model.

Theranostics·2026
Same author

Head and Neck Squamous Cell Carcinoma Patient-Derived Cancer-Associated Fibroblasts Undergo Senescence While Retaining Protumorigenic Properties After Ex Vivo Irradiation.

International journal of radiation oncology, biology, physics·2026
Same author

The radiotherapy induced cyclic GMP-AMP-synthase re-localization and immune signature predicts HNSCC treatment efficacy.

Communications medicine·2026

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Biology

Background:

  • Solid tumors frequently contain hypoxic cells, negatively impacting radiotherapy outcomes.
  • Optimal scheduling of combined modality treatments, especially those targeting hypoxic cells, depends on understanding hypoxic cell turnover.
  • Previous work established a double bioreductive hypoxic marker assay for detecting tumor hypoxia changes.

Purpose of the Study:

  • To determine the hypoxic cell turnover rates in three different tumor models using a double bioreductive hypoxic marker assay.
  • To investigate the potential importance of hypoxic cell turnover for optimizing combined modality treatment scheduling.

Main Methods:

  • Employed a double bioreductive hypoxic marker assay with pimonidazole and CCI-103F.
  • Administered pimonidazole at variable times and CCI-103F at a fixed time before tumor harvest.

Related Experiment Videos

  • Defined hypoxic cell turnover as the loss of pimonidazole staining relative to CCI-103F staining.

    • Main Results:

    • Hypoxic cell turnover half-lives were 17 h (C38 colon carcinoma), 23 h (MEC82 xenograft), and 49 h (SCCNij3 xenograft).
    • In C38 and MEC82, pimonidazole-positive areas decreased within 24 h, with cell debris appearing in necrotic regions.
    • Most hypoxic cells disappeared within 48 h in C38 and MEC82, while viable pimonidazole-labeled cells persisted for over 5 days in SCCNij3.

    Conclusions:

    • The double hypoxia marker assay effectively quantifies both the proportion and lifespan of hypoxic tumor cells.
    • Significant variations in hypoxic cell turnover rates exist across different tumor lines, with half-lives ranging from 17 to 49 hours.
    • These findings highlight the importance of considering tumor-specific hypoxic cell turnover for effective treatment strategies.